IL10

(redirected from Cytokine synthesis inhibitory factor)

IL10

A gene on chromosome 1q31-q32 that encodes interleukin-10, a cytokine produced primarily by monocytes, but also by lymphocytes, which inhibits the synthesis of a number of cytokines (including IFN-gamma, IL-2, IL-3, TNF and GM-CSF) produced by activated macrophages and helper T cells. IL10 has pleiotropic effects in immunoregulation and inflammation. It downregulates expression of Th1 cytokines, MHC class-II antigens and co-stimulatory molecules on macrophages, and it enhances B cell survival, proliferation and antibody production. It can block NF-kappa B activity, and is involved in regulating the JAK-STAT signalling pathway.

Molecular pathology
IL10 mutations are associated with an increased susceptibility to HIV-1 infection and rheumatoid arthritis.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
Interleukin-10, human cytokine synthesis inhibitory factor (CSIF), is group of related proteins made by leukocytes and other body cells.
* To provide a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10).
* To review Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The report provides comprehensive information on the Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
* The report provides a snapshot of the global therapeutic landscape for Interleukin 10 (Cytokine Synthesis Inhibitory Factor or CISF or IL10)
In the preclinical model of stroke used in the study, animals that received treatment with MultiStem versus placebo showed statistically significant increases in the percentage of T regulatory (Treg) cells, which may play an important role in the healing process, and decreases in inflammatory T cells, which are believed to exacerbate damage in the brain following a stroke; a statistically significant reduction in the pro-inflammatory cytokine levels of IL-1[beta] and TNF-[alpha]; and a statistically significant increase in levels of the anti-inflammatory cytokine IL-10, also known as human cytokine synthesis inhibitory factor (CSIF).

Full browser ?